High-nickel cathode LiNi_(0.8)Co_(0.1)Mn_(0.1)O_(2)(NCM811)could enable lithium-ion batteries(LIBs)with high energy density.However,excessive decomposition of the electrolyte would happen in the high operating voltage...High-nickel cathode LiNi_(0.8)Co_(0.1)Mn_(0.1)O_(2)(NCM811)could enable lithium-ion batteries(LIBs)with high energy density.However,excessive decomposition of the electrolyte would happen in the high operating voltage range.In addition,the utilization of flammable organic solvents would increase safety risks in the high temperature environment.Herein,an electrolyte consisting of flame-retardant solvents with lower highest occupied molecular orbital(HOMO)level and LiDFOB salt is proposed to address above two issues.As a result,a thin and robust cathode-electrolyte interface containing rich LiF and Li-B-O compounds is formed on the cathode to effectively suppress electrolyte decomposition in the high operating voltage.The NCM811||Li cell paired with this designed electrolyte possesses a capacity retention of 72%after 300 cycles at 55℃.This work provides insights into developing electrolyte for stable high-nickel cathode operated in the high temperature.展开更多
Dysfunction of the Hippo pathway enables cells to evade contact inhibition and provides advantages for cancerous overgrowth.However,for a significant portion of human cancer,how Hippo signaling is perturbed remains un...Dysfunction of the Hippo pathway enables cells to evade contact inhibition and provides advantages for cancerous overgrowth.However,for a significant portion of human cancer,how Hippo signaling is perturbed remains unknown.To answer this question,we performed a genome-wide screening for genes that affect the Hippo pathway in Drosophila and cross-referenced the hit genes with human cancer genome.In our screen,Prosap was identified as a novel regulator of the Hippo pathway that potently affects tissue growth.Interestingly,a mammalian homolog of Prosap,SHANK2,is the most frequently amplified gene on 11 q13,a major tumor amplicon in human cancer.Gene amplification profile in this 11q13 amplicon clearly indicates selective pressure for SHANK2 amplification.More importantly,across the human cancer genome,SHANK2 is the most frequently amplified gene that is not located within the Myc amplicon.Further studies in multiple human cell lines confirmed that SHANK2 overexpression causes deregulation of Hippo signaling through competitive binding for a LATS1 activator,and as a potential oncogene,SHANK2 promotes cellular transformation and tumor formation in vivo.In cancer cell lines with deregulated Hippo pathway,depletion of SHANK2 restores Hippo signaling and ceases cellular proliferation.Taken together,these results suggest that SHANK2 is an evolutionarily conserved Hippo pathway regulator,commonly amplified in human cancer and potently promotes cancer.Our study for the first time illustrated oncogenic function of SHANK2,one of the most frequently amplified gene in human cancer.Furthermore,given that in normal adult tissues,SHANK2 s expression is largely restricted to the nervous system,SHANK2 may represent an interesting target for anticancer therapy.展开更多
This study aimed to investigate the status of and changes in the vaccination willingness of patients with breast cancer to increase the coronavirus disease 2019(COVID-19)vaccination rate among these patients.The first...This study aimed to investigate the status of and changes in the vaccination willingness of patients with breast cancer to increase the coronavirus disease 2019(COVID-19)vaccination rate among these patients.The first survey included patients fromthe FifthMedical Center of the PLA GeneralHospitalwho participated in the Society of ClinicalOncology Breast Cancer CommitteeNCP-02 study conducted from September 16 to December 31,2021.The second survey was conducted from December 9 to December 26,2022,for those who had not received vaccines previously.In total,266 patients completed two questionnaires.A total of 143 patients(53.8%)changed their willingness to receive the vaccination.Among them,45,who were initially unwilling to be vaccinated,changed their stance to become hesitant and 15 changed to become willing.Among those with hesitant attitudes toward vaccines,45 changed their stance to become willing,and 28 changed to become unwilling;10 patients with willing attitudes toward vaccines changed to become hesitant.Those who received surgery(odds ratio(OR),4.24;95%confidence interval(CI),1.45–12.42;P=0.01)andwho lived with older adults or children(OR,2.03;95%CI,1.13–3.62;P=0.02)were more likely to change their attitudes toward COVID-19 vaccines.This finding suggested that patients with breast cancer were cautious about receiving the COVID-19 vaccine.Multiple methods should be used to promote vaccination and reduce vaccine hesitancy.展开更多
基金supported by the National Key Research and Development Program of China(2022YFB3803400)。
文摘High-nickel cathode LiNi_(0.8)Co_(0.1)Mn_(0.1)O_(2)(NCM811)could enable lithium-ion batteries(LIBs)with high energy density.However,excessive decomposition of the electrolyte would happen in the high operating voltage range.In addition,the utilization of flammable organic solvents would increase safety risks in the high temperature environment.Herein,an electrolyte consisting of flame-retardant solvents with lower highest occupied molecular orbital(HOMO)level and LiDFOB salt is proposed to address above two issues.As a result,a thin and robust cathode-electrolyte interface containing rich LiF and Li-B-O compounds is formed on the cathode to effectively suppress electrolyte decomposition in the high operating voltage.The NCM811||Li cell paired with this designed electrolyte possesses a capacity retention of 72%after 300 cycles at 55℃.This work provides insights into developing electrolyte for stable high-nickel cathode operated in the high temperature.
基金This work was supported by the National Natural Science Foundation of China （Grant Nos. 41172110 and 61107090） and Shandong Provincial Natural Science Foundation （Grant No. ZR2011BZ007）.
基金This work was supported by the major scientific research project(Grant Nos.2017YFA0504503,2019YFA0802001 and 2017YFA0103601)the National Natural Science Foundation of China(Grant Nos.81972600,31530043 and 31625017)the Strategic Priority Research Program of Chinese Academy of Sciences,Grant No.XDB19000000.
文摘Dysfunction of the Hippo pathway enables cells to evade contact inhibition and provides advantages for cancerous overgrowth.However,for a significant portion of human cancer,how Hippo signaling is perturbed remains unknown.To answer this question,we performed a genome-wide screening for genes that affect the Hippo pathway in Drosophila and cross-referenced the hit genes with human cancer genome.In our screen,Prosap was identified as a novel regulator of the Hippo pathway that potently affects tissue growth.Interestingly,a mammalian homolog of Prosap,SHANK2,is the most frequently amplified gene on 11 q13,a major tumor amplicon in human cancer.Gene amplification profile in this 11q13 amplicon clearly indicates selective pressure for SHANK2 amplification.More importantly,across the human cancer genome,SHANK2 is the most frequently amplified gene that is not located within the Myc amplicon.Further studies in multiple human cell lines confirmed that SHANK2 overexpression causes deregulation of Hippo signaling through competitive binding for a LATS1 activator,and as a potential oncogene,SHANK2 promotes cellular transformation and tumor formation in vivo.In cancer cell lines with deregulated Hippo pathway,depletion of SHANK2 restores Hippo signaling and ceases cellular proliferation.Taken together,these results suggest that SHANK2 is an evolutionarily conserved Hippo pathway regulator,commonly amplified in human cancer and potently promotes cancer.Our study for the first time illustrated oncogenic function of SHANK2,one of the most frequently amplified gene in human cancer.Furthermore,given that in normal adult tissues,SHANK2 s expression is largely restricted to the nervous system,SHANK2 may represent an interesting target for anticancer therapy.
基金supported by the Emergency Key Program of Guangzhou Laboratory(EKPG21-30-4)Beijing Science and Technology Plan(Z181100001718215).
文摘This study aimed to investigate the status of and changes in the vaccination willingness of patients with breast cancer to increase the coronavirus disease 2019(COVID-19)vaccination rate among these patients.The first survey included patients fromthe FifthMedical Center of the PLA GeneralHospitalwho participated in the Society of ClinicalOncology Breast Cancer CommitteeNCP-02 study conducted from September 16 to December 31,2021.The second survey was conducted from December 9 to December 26,2022,for those who had not received vaccines previously.In total,266 patients completed two questionnaires.A total of 143 patients(53.8%)changed their willingness to receive the vaccination.Among them,45,who were initially unwilling to be vaccinated,changed their stance to become hesitant and 15 changed to become willing.Among those with hesitant attitudes toward vaccines,45 changed their stance to become willing,and 28 changed to become unwilling;10 patients with willing attitudes toward vaccines changed to become hesitant.Those who received surgery(odds ratio(OR),4.24;95%confidence interval(CI),1.45–12.42;P=0.01)andwho lived with older adults or children(OR,2.03;95%CI,1.13–3.62;P=0.02)were more likely to change their attitudes toward COVID-19 vaccines.This finding suggested that patients with breast cancer were cautious about receiving the COVID-19 vaccine.Multiple methods should be used to promote vaccination and reduce vaccine hesitancy.
